Over the forecast period, the market growth is anticipated to be boosted by the rising number of cases of seasonal affective disorder. For instance, the Royal College of Psychiatrists reported in an article from April 2015 that 3 out of 100 Britons have major winter depressions. Due to the rising number of seasonal affective disorder (SAD) cases in the region, North America is anticipated to dominate the global market for SAD. For instance, a Boston University paper from October 2019 claims that 10 million Americans suffer from seasonal affective disorder, with women four times as likely as males to receive a diagnosis. Seasonal affective disorder is increasing due to the rising prevalence of bipolar disorders, which is predicted to accelerate market expansion. For instance, according to the Global Burden of Diseases report published in December 2017 by the Institute for Health Metrics and Evaluation (IHME), the percentage of the world's population who had bipolar disorder in 2017 was 0.6% (46 million), with 0.55% of men and 0.65% of women affected.
According to Coherent Market Insights, during the projected period (2020-2027), the market for Seasonal Affective Disorder is anticipated to grow at a CAGR of 5.5%, reaching an estimated value of US$ 544.7 million in 2020.
Major Players in the Seasonal Affective Disorder Industry:
1. Pfizer Inc.,
The company was established in 1849, and Manhattan, New York City, is where its corporate headquarters are situated. Through the creation of pharmaceuticals and vaccines, Pfizer seeks to enhance the fields of immunology, cancer, the heart, endocrinology, and neurology. In October 2022, the business successfully acquired Biohaven Pharma's calcitonin gene-related peptide programmes. Pfizer purchased Amplyx Pharmaceuticals in April 2021, which included the rights to the antifungal drug fosmanogepix (APX001).
2. GlaxoSmithKline plc,
The company was established in 2000, and London, England serves as its headquarters. GSK creates medications for conditions like diabetes, cancer, worms, and mental health. Three unsolicited proposals to purchase Unilever's Consumer Healthcare sector were received by the company in January 2022, according to the report. In November 2022, GSK published upbeat Phase IIa research findings for a brand-new, ground-breaking prospective therapy for tuberculosis patients.
3. Bristol-Myers Squibb Company
It was founded in 1887, and it is headquartered in New York, USA. The company makes prescription medications and biologics for a variety of illnesses, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders. BMS announced that it would buy Turning Point Therapeutics Inc. for $4.1 billion in cash in June 2022.
4. Eli Lilly And Company,
The business was established in 1876 and is headquartered in Indianapolis, Indiana. The company's primary areas of interest include pharmaceutical product development, marketing, and promotion. Disarm Therapeutics, which offers cutting-edge therapies for axonal degeneration, declared in October 2020 that Lilly would purchase it. The company would purportedly focus on creating medications for autoimmune conditions, diabetes, obesity, and Alzheimer's in 2023.
5. Johnson & Johnson Services, Inc.,
The company was established in 1886 and has its main office in New Brunswick, New Jersey. In addition to consumer packaged goods, the company also creates medical devices and drugs. Johnson & Johnson paid $6.5 billion to purchase Momenta Pharmaceuticals in November 2020. Johnson & Johnson declared in November 2022 that it will pay $16.6 billion to buy Abiomed Inc. On December 22, the deal became final.
6. Teva Pharmaceutical Industries Ltd.
The corporation was founded in 1901 and has its headquarters in Tel Aviv, Israel. Although its primary area of expertise is in generic drugs, it also has some additional business interests in active pharmaceutical ingredients and, to a lesser extent, patented drugs. The aggressive climate targets set by Teva will have received external validation on January 19, 2023, thanks to the Science Based Targets programme (SBTi). Teva said on January 9th, 2023 that the federal opioids deal will proceed after receiving strong support from the states.
7. Novartis
The company was founded in March 1996 and has its main offices in Basel, Switzerland, and Cambridge, Massachusetts, in the United States. Novartis provides coverage for all types of medications, including authorization, over-the-counter, immunisations, diagnostics, eyewear, and veterinary care. Through its firms, Novartis engages in a number of direct activities, including managing, advertising, operations, and research.
Definition: As a major depressive disorder with a seasonal pattern, seasonal affective disorder (SAD) has been recognised and is now listed in the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition. Seasonality, or changing weather patterns, has a significant impact on people everywhere.
